167 related articles for article (PubMed ID: 10972086)
1. Immunogenicity of an eight amino acid domain shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and antigenic analysis.
Silvestris F; Cocco T; Cafforio P; Calvani N; Dammacco F
Mol Med; 2000 Jun; 6(6):494-508. PubMed ID: 10972086
[TBL] [Abstract][Full Text] [Related]
2. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease.
Silvestris F; Cafforio P; Tucci M; Del Prete A; Dammacco F
Mol Med; 2000 Jun; 6(6):509-26. PubMed ID: 10972087
[TBL] [Abstract][Full Text] [Related]
3. Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients.
Silvestris F; Nagata S; Cafforio P; Silvestris N; Dammacco F
J Exp Med; 1996 Dec; 184(6):2287-300. PubMed ID: 8976184
[TBL] [Abstract][Full Text] [Related]
4. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T lymphocytes specific for the synthetic VEINCTR peptide, a sequence found within the Fas molecule and env gp120 in the blood of HIV-1 seropositive individuals.
Moukrim Z; Achour A
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):439-44. PubMed ID: 7580839
[TBL] [Abstract][Full Text] [Related]
6. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
Peachman KK; Karasavvas N; Chenine AL; McLinden R; Rerks-Ngarm S; Jaranit K; Nitayaphan S; Pitisuttithum P; Tovanabutra S; Zolla-Pazner S; Michael NL; Kim JH; Alving CR; Rao M
PLoS One; 2015; 10(12):e0143895. PubMed ID: 26625359
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera.
Metlas R; Trajkovic D; Srdic T; Veljkovic V; Colombatti A
AIDS Res Hum Retroviruses; 1999 May; 15(7):671-7. PubMed ID: 10331446
[TBL] [Abstract][Full Text] [Related]
8. Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120.
Karle S; Nishiyama Y; Taguchi H; Zhou YX; Luo J; Planque S; Hanson C; Paul S
Vaccine; 2003 Mar; 21(11-12):1213-8. PubMed ID: 12559800
[TBL] [Abstract][Full Text] [Related]
9. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
10. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
[TBL] [Abstract][Full Text] [Related]
13. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
14. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
15. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
16. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
Sherefa K; Sällberg M; Sönnerborg A
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
[TBL] [Abstract][Full Text] [Related]
17. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
Hunt JC; Golden AM; Lund JK; Gürtler LG; Zekeng L; Obiang J; Kaptué L; Hampl H; Vallari A; Devare SG
AIDS Res Hum Retroviruses; 1997 Aug; 13(12):995-1005. PubMed ID: 9264286
[TBL] [Abstract][Full Text] [Related]
18. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
Neurath AR; Strick N; Li YY; Jiang S
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
[TBL] [Abstract][Full Text] [Related]
19. Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb.
Fadeel B; Thorpe J; Chiodi F
Int Immunol; 1995 Dec; 7(12):1967-75. PubMed ID: 8746566
[TBL] [Abstract][Full Text] [Related]
20. Comparing antigenicity and immunogenicity of engineered gp120.
Selvarajah S; Puffer B; Pantophlet R; Law M; Doms RW; Burton DR
J Virol; 2005 Oct; 79(19):12148-63. PubMed ID: 16160142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
